Compare Hims and Hers Health Inc (HIMS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Zimmer Biomet Holdings Inc — how do they compare? Hims and Hers Health Inc trades at $32.37 (market cap $7.57B), while Zimmer Biomet Holdings Inc trades at $89.74 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.3× Hims and Hers Health Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | ZBH | |
|---|---|---|
Market Cap | $7.57B | $17.36B |
Sector | Health | Health |
52-Week High | $66.18 | $107.71 |
52-Week Low | $14.52 | $79.58 |
Enterprise Value | $7.95B | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.
The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
